Our services have diverse applications that can be useful for many professionals in different fields of knowledge.
Who can benefit from our services?
Our services are aimed at universities, research centers, health professionals, pharmaceutical companies, food companies, and clinical analysis laboratories that develop their activity in the field of metabolic diseases. The applications of our services are diverse:
We are an innovative company, specialized in nuclear magnetic resonance, and we seek to provide the best service to our customers. For this reason, we continuously seek partners for national and international projects for the investigation of new markers, analytical methods, new matrices and new treatments that promote the study, prevention, diagnosis and treatment of metabolic disorders in a more careful and accurate way.
Changes in the lifestyle of developed and emerging countries favor the exponential appearance of metabolic disorders such as obesity, diabetes, and metabolic syndrome, among others. The appearance of these disorders has drastically increased the number of cardiovascular accidents, placing cardiovascular diseases as the leading cause of death worldwide. According to the World Health Organization, in 2015 there were 17.7 million deaths related to cardiovascular diseases, which accounted for 31% of all deaths worldwide.
In this context, the advanced characterization of lipoproteins, glycoproteins and low molecular weight metabolites associated with risk, complemented by the lipid profile, is of great help for the diagnosis and monitoring of pathologies related to disorders of metabolism, allowing the evaluation of the health status of patients with metabolic disorders and inflammatory processes, individuals with a higher risk of developing diabetes and cardiovascular accidents.
Advanced metabolomic profiling including lipoprotein, glycoprotein, low molecular weight metabolites, as well as lipid families is an excellent tool for nutritional studies, from post-pandrial studies to interventions investigating the relationship between dietary intake and its relationship to health status. The metabolomic study allows us to know the metabolic changes of individuals who have undergone nutritional interventions, both in healthy people and in people suffering from a disease.
Cancer is the second leading cause of death in Europe, the first among those under 65 years of age. In Spain, more than 200,000 people are diagnosed each year. A timely diagnosis can prevent its development.
For this reason, the study of metabolism for the identification of biomarkers, either for their prevention, for diagnosis, for patient stratification or to follow-up patients, is of great interest in order to acquire new complementary tools for improving people’s health.
The advanced characterization of lipoproteins, glycoproteins, low molecular weight metabolites and/or the lipidomic profile are promising tools for the study of inflammatory processes and metabolic alterations in order to obtain metabolic traces, profiles or signatures that characterize the course of cancer. Said tools can be used in biofluids from patients, such as serum, urine or feces, although studies can also be carried out in tissues, either from patients (tumor tissue or primary cultures) or basic studies on cell lines.
Chronic kidney disease
This disease involves a gradual loss of kidney function. The kidneys filter wastes and excess fluids from the blood, which are eliminated through urine. Chronic kidney disease is considered by the World Health Organization as a global public health problem, directly related to diabetes, hypertension and advanced age of the population.
In this context, advanced metabolomic characterization including lipoprotein profiling, glycoproteins, low molecular weight metabolites, as well as lipid families is an excellent tool to assess the health status of these patients, with the aim of improving the diagnosis and treatment of the disease beyond traditional markers/tools.
Metabolic disease in fetal growth/infancy
Advanced metabolomic profiling including profiling of lipoproteins, glycoproteins, low molecular weight metabolites, as well as lipid families is an excellent tool to investigate the relationship between mother and baby. Blood or cord blood analysis allows the study of short and long term metabolic effects of the offspring and their correlation with lifelong health. It also allows the study of pregnancy-related complications such as pre-eclampsia and gestational diabetes.
Advanced metabolomic profiling that includes profiling of lipoproteins, glycoproteins, low molecular weight metabolites, as well as lipid families. It is an excellent tool to investigate autoimmune diseases. Specifically, this advanced profiling includes both new established markers of chronic inflammation such as GlycA and GlycB, as well as metabolic biomarkers with the aim of improving diagnosis, understanding disease prognosis and/or studying treatments for the disease beyond traditional markers.